🚀 VC round data is live in beta, check it out!
Gan and Lee Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gan and Lee and similar public comparables like Caliway Biopharmaceuticals, Hebei Changshan, Shanghai RAAS, Xenon Pharmaceuticals and more.
Gan and Lee Overview
About Gan and Lee
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
Founded
1998
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$5B
Gan and Lee Financials
Gan and Lee reported last 12-month revenue of $655M and EBITDA of $219M.
In the same LTM period, Gan and Lee generated $219M in EBITDA and $174M in net income.
Revenue (LTM)
Gan and Lee P&L
In the most recent fiscal year, Gan and Lee reported revenue of $446M and EBITDA of $130M.
Gan and Lee expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $655M | XXX | $446M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $334M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $219M | XXX | $130M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $174M | XXX | $90M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gan and Lee Stock Performance
Gan and Lee has current market cap of $6B, and enterprise value of $5B.
Market Cap Evolution
Gan and Lee's stock price is $9.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $6B | -0.6% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGan and Lee Valuation Multiples
Gan and Lee trades at 7.8x EV/Revenue multiple, and 23.4x EV/EBITDA.
EV / Revenue (LTM)
Gan and Lee Financial Valuation Multiples
As of April 10, 2026, Gan and Lee has market cap of $6B and EV of $5B.
Equity research analysts estimate Gan and Lee's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gan and Lee has a P/E ratio of 32.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 7.8x | XXX | 11.5x | XXX | XXX | XXX |
| EV/EBITDA | 23.4x | XXX | 39.3x | XXX | XXX | XXX |
| EV/EBIT | 32.9x | XXX | 72.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 15.3x | XXX | XXX | XXX |
| P/E | 32.0x | XXX | 61.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 361.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gan and Lee Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gan and Lee Margins & Growth Rates
Gan and Lee's revenue in the last 12 month grew by 26%.
Gan and Lee's rule of 40 is 62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gan and Lee's rule of X is 106% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gan and Lee Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 56% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 62% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 106% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gan and Lee Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Caliway Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hebei Changshan | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai RAAS | XXX | XXX | XXX | XXX | XXX | XXX |
| Xenon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Henlius Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gan and Lee M&A Activity
Gan and Lee acquired XXX companies to date.
Last acquisition by Gan and Lee was on XXXXXXXX, XXXXX. Gan and Lee acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gan and Lee
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGan and Lee Investment Activity
Gan and Lee invested in XXX companies to date.
Gan and Lee made its latest investment on XXXXXXXX, XXXXX. Gan and Lee invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gan and Lee
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gan and Lee
| When was Gan and Lee founded? | Gan and Lee was founded in 1998. |
| Where is Gan and Lee headquartered? | Gan and Lee is headquartered in China. |
| Is Gan and Lee publicly listed? | Yes, Gan and Lee is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Gan and Lee? | Gan and Lee trades under 603087 ticker. |
| When did Gan and Lee go public? | Gan and Lee went public in 2020. |
| Who are competitors of Gan and Lee? | Gan and Lee main competitors are Caliway Biopharmaceuticals, Hebei Changshan, Shanghai RAAS, Xenon Pharmaceuticals. |
| What is the current market cap of Gan and Lee? | Gan and Lee's current market cap is $6B. |
| What is the current revenue of Gan and Lee? | Gan and Lee's last 12 months revenue is $655M. |
| What is the current revenue growth of Gan and Lee? | Gan and Lee revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Gan and Lee? | Current revenue multiple of Gan and Lee is 7.8x. |
| Is Gan and Lee profitable? | Yes, Gan and Lee is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gan and Lee? | Gan and Lee's last 12 months EBITDA is $219M. |
| What is Gan and Lee's EBITDA margin? | Gan and Lee's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Gan and Lee? | Current EBITDA multiple of Gan and Lee is 23.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.